193 related articles for article (PubMed ID: 36543375)
1. Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab.
Benelli R; Costa D; Salvini L; Tardito S; Tosetti F; Villa F; Zocchi MR; Poggi A
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36543375
[TBL] [Abstract][Full Text] [Related]
2. Priming of Colorectal Tumor-Associated Fibroblasts with Zoledronic Acid Conjugated to the Anti-Epidermal Growth Factor Receptor Antibody Cetuximab Elicits Anti-Tumor Vδ2 T Lymphocytes.
Fernandez JLC; Benelli R; Costa D; Campioli A; Tavella S; Zocchi MR; Poggi A
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765569
[TBL] [Abstract][Full Text] [Related]
3. EGFR-Targeted Antibody-Drug Conjugate to Different Aminobisphosphonates: Direct and Indirect Antitumor Effects on Colorectal Carcinoma Cells.
Pisheh L; Matis S; Taglieri M; Di Gregorio L; Benelli R; Poggi A
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610932
[TBL] [Abstract][Full Text] [Related]
4. Antibody-Drug Conjugate Made of Zoledronic Acid and the Anti-CD30 Brentuximab-Vedotin Exert Anti-Lymphoma and Immunostimulating Effects.
Morelli F; Matis S; Benelli R; Salvini L; Zocchi MR; Poggi A
Cells; 2024 May; 13(10):. PubMed ID: 38786084
[TBL] [Abstract][Full Text] [Related]
5. Nanoformulated Zoledronic Acid Boosts the Vδ2 T Cell Immunotherapeutic Potential in Colorectal Cancer.
Di Mascolo D; Varesano S; Benelli R; Mollica H; Salis A; Zocchi MR; Decuzzi P; Poggi A
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31906080
[TBL] [Abstract][Full Text] [Related]
6. Zoledronate Triggers Vδ2 T Cells to Destroy and Kill Spheroids of Colon Carcinoma: Quantitative Image Analysis of Three-Dimensional Cultures.
Varesano S; Zocchi MR; Poggi A
Front Immunol; 2018; 9():998. PubMed ID: 29867975
[TBL] [Abstract][Full Text] [Related]
7. A pH-responsive cetuximab-conjugated DMAKO-20 nano-delivery system for overcoming K-ras mutations and drug resistance in colorectal carcinoma.
Song H; Li H; Shen X; Liu K; Feng H; Cui J; Wei W; Sun X; Fan Q; Bao W; Zhou H; Qian L; Nie H; Cheng X; Du Z
Acta Biomater; 2024 Mar; 177():456-471. PubMed ID: 38331131
[TBL] [Abstract][Full Text] [Related]
8. Bacillus Calmette-Guerin (BCG) induces superior anti-tumour responses by Vδ2+ T cells compared with the aminobisphosphonate drug zoledronic acid.
Fenn J; Ridgley LA; White A; Sarfas C; Dennis M; Dalgleish A; Reljic R; Sharpe S; Bodman-Smith M
Clin Exp Immunol; 2022 Jun; 208(3):301-315. PubMed ID: 35404420
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo expansion and activation of Vγ9Vδ2 T cells by CELMoDs in combination with zoledronic acid.
Inoue Y; Oda A; Maeda Y; Sumitani R; Oura M; Sogabe K; Maruhashi T; Takahashi M; Fujii S; Nakamura S; Miki H; Hiasa M; Teramachi J; Harada T; Abe M
Int J Hematol; 2024 Jun; 119(6):626-630. PubMed ID: 38581458
[TBL] [Abstract][Full Text] [Related]
10. Anti-PD1 does not improve pyroptosis induced by γδ T cells but promotes tumor regression in a pleural mesothelioma mouse model.
Lui KS; Ye Z; Chan HC; Tanaka Y; Cheung AKL
Front Immunol; 2023; 14():1282710. PubMed ID: 38077396
[TBL] [Abstract][Full Text] [Related]
11. BTN2A1, an immune checkpoint targeting Vγ9Vδ2 T cell cytotoxicity against malignant cells.
Cano CE; Pasero C; De Gassart A; Kerneur C; Gabriac M; Fullana M; Granarolo E; Hoet R; Scotet E; Rafia C; Herrmann T; Imbert C; Gorvel L; Vey N; Briantais A; le Floch AC; Olive D
Cell Rep; 2021 Jul; 36(2):109359. PubMed ID: 34260935
[TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid renders human M1 and M2 macrophages susceptible to Vδ2
Fowler DW; Copier J; Dalgleish AG; Bodman-Smith MD
Cancer Immunol Immunother; 2017 Sep; 66(9):1205-1215. PubMed ID: 28501938
[TBL] [Abstract][Full Text] [Related]
13. Zoledronate can induce colorectal cancer microenvironment expressing BTN3A1 to stimulate effector γδ T cells with antitumor activity.
Zocchi MR; Costa D; Venè R; Tosetti F; Ferrari N; Minghelli S; Benelli R; Scabini S; Romairone E; Catellani S; Profumo A; Poggi A
Oncoimmunology; 2017; 6(3):e1278099. PubMed ID: 28405500
[TBL] [Abstract][Full Text] [Related]
14. EGFR-targeted hybrid lipid nanoparticles for chemo-photothermal therapy against colorectal cancer cells.
Fang F; Zhang X; Tang J; Wang Y; Xu J; Sun Y
Chem Phys Lipids; 2023 Mar; 251():105280. PubMed ID: 36634728
[TBL] [Abstract][Full Text] [Related]
15. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
16. Terminal α2,6-sialylation of epidermal growth factor receptor modulates antibody therapy response of colorectal cancer cells.
Rodrigues JG; Duarte HO; Gomes C; Balmaña M; Martins ÁM; Hensbergen PJ; de Ru AH; Lima J; Albergaria A; van Veelen PA; Wuhrer M; Gomes J; Reis CA
Cell Oncol (Dordr); 2021 Aug; 44(4):835-850. PubMed ID: 33847896
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and Characterization of Cetuximab-Docetaxel and Panitumumab-Docetaxel Antibody-Drug Conjugates for EGFR-Overexpressing Cancer Therapy.
Glatt DM; Beckford Vera DR; Prabhu SS; Mumper RJ; Luft JC; Benhabbour SR; Parrott MC
Mol Pharm; 2018 Nov; 15(11):5089-5102. PubMed ID: 30226780
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab-Ag
Hashemkhani M; Demirci G; Bayir A; Muti A; Sennaroglu A; Mohammad Hadi L; Yaghini E; Loizidou M; MacRobert AJ; Yagci Acar H
Nanoscale; 2021 Sep; 13(35):14879-14899. PubMed ID: 34533177
[TBL] [Abstract][Full Text] [Related]
19. Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma.
Lang JM; Kaikobad MR; Wallace M; Staab MJ; Horvath DL; Wilding G; Liu G; Eickhoff JC; McNeel DG; Malkovsky M
Cancer Immunol Immunother; 2011 Oct; 60(10):1447-60. PubMed ID: 21647691
[TBL] [Abstract][Full Text] [Related]
20. EGFR Targeted Cetuximab-Valine-Citrulline (vc)-Doxorubicin Immunoconjugates- Loaded Bovine Serum Albumin (BSA) Nanoparticles for Colorectal Tumor Therapy.
Ye Z; Zhang Y; Liu Y; Liu Y; Tu J; Shen Y
Int J Nanomedicine; 2021; 16():2443-2459. PubMed ID: 33814909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
